Cingulate Inc.
NASDAQ: CING0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Shane J. Schaffer
- Employees
- 13
- Headquarters
- Kansas City, United States
- IPO year
- 2021
- Market cap
- $27.0M
- Website
- https://www.cingulate.com
Loading CING…
Loading profile data…Frequently asked questions about CING
What does Cingulate Inc. (CING) do?
Cingulate Inc. is a biopharmaceutical enterprise currently in its clinical development phase, dedicated to devising therapeutic options for attention-deficit/hyperactivity disorder (ADHD). Leading its pipeline for ADHD are two drug candidates: CTx-1301 (dexmethylphenidate), which is currently progressing through Phase 3 clinical trials, and CTx-...
Where does CING trade?
Cingulate Inc. (CING) trades on the NASDAQ Capital Market.
What sector is CING in?
Cingulate Inc. (CING) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Cingulate Inc.?
Shane J. Schaffer is the chief executive officer of Cingulate Inc. (CING).
Where is Cingulate Inc. headquartered?
Cingulate Inc. is headquartered in United States.
Does CING pay a dividend?
Cingulate Inc. (CING) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CING go public?
Cingulate Inc. (CING) completed its initial public offering in 2021.